Introduction to Biotechnology in Drug Formulation
Start with the big picture
Biotech drugs include recombinant proteins such as insulin and monoclonal antibodies, as well as mRNA vaccines. Compared with small-molecule drugs, biologics are more complex and may require specialized formulation and cold-chain storage. Formulation strategies such as buffers, stabilizers, and freeze-drying help maintain stability and reduce risks such as denaturation, aggregation, or degradation. Biotechnology can enable highly specific and potent medicines, while cost and handling requirements remain important limitations. The topic also introduces biosimilars, which must show high similarity—but not identity—to their reference biologics, and outlines the role of regulatory frameworks from agencies such as the FDA, EMA, and WHO.
What you'll learn
- Describe how biotechnology contributes to biologic drug development and manufacture.
- Identify examples of biotech medicines and distinguish them from conventional small-molecule drugs.
- Explain why biologic stability affects formulation, storage, and handling.
- Recognize the purpose of stabilizers, buffers, and freeze-drying in biologic formulations.
- Summarize how biosimilars differ from generics and reference biologics.
Continue your study
Work through the complete notes and reinforce the topic with the study tools available in the full lesson.
